Relative efficacies of cannabinoid CB1 receptor agonists in the mouse brain

被引:77
|
作者
Burkey, TH
Quock, RM
Consroe, P
Ehlert, FJ
Hosohata, Y
Roeske, WR
Yamamura, HI
机构
[1] UNIV ARIZONA,HLTH SCI CTR,COLL MED,DEPT PHARMACOL,TUCSON,AZ 85724
[2] UNIV ARIZONA,HLTH SCI CTR,COLL MED,DEPT PHARMACOL & TOXICOL,TUCSON,AZ 85724
[3] UNIV ARIZONA,HLTH SCI CTR,COLL MED,DEPT BIOCHEM,TUCSON,AZ 85724
[4] UNIV ARIZONA,HLTH SCI CTR,COLL MED,DEPT PSYCHIAT,TUCSON,AZ 85724
[5] UNIV ARIZONA,HLTH SCI CTR,COLL MED,PROGRAM NEUROSCI,TUCSON,AZ 85724
[6] UNIV ILLINOIS,COLL MED,DEPT BIOMED SCI,ROCKFORD,IL 61107
[7] UNIV CALIF IRVINE,DEPT PHARMACOL,IRVINE,CA 92717
关键词
cannabinoid; cannabinoid receptor; drug efficacy; brain; mouse; (partial agonist); tetrahydrocannabinol;
D O I
10.1016/S0014-2999(97)01255-7
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
We measured (-)-5-(1,1-dimethylheptyl)-2-[5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]-phenol (CP 55,940)-, (-)11-OH-Delta (8)-tetrahydrocannabinol-dimethylheptyl (HU-210)-, anandamide- and Delta(9)-tetrahydrocannabinol-stimulated G protein activation in mouse brain using the [S-35]GTPyS functional assay. The K-i values for these drugs were determined by agonist competition binding with the cannabinoid CB, receptor antagonist [H-3]N-(piperidin-1-yl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamidehydrochloride ([H-3]SR141716A). This information was used to calculate the efficacy for drug stimulation of G protein activity. The rank order of efficacy was CP 55,940 > HU-210 > anandamide > Delta(9)-tetrahydrocannabinol with the latter two drugs being partial agonists. Since efficacy values relate receptor occupancy to functional responses, we believe efficacy values are a better measure of drug-mediated functional responses compared with measurements of drug potency. (C) 1997 Elsevier Science B.V.
引用
收藏
页码:295 / 298
页数:4
相关论文
共 50 条
  • [1] The CB1 cannabinoid receptor in the brain
    Howlett, AC
    NEUROBIOLOGY OF DISEASE, 1998, 5 (06) : 405 - 416
  • [2] Recent CB1 Cannabinoid Receptor Antagonists and Inverse Agonists
    Seltzman, Herbert H.
    DRUG DEVELOPMENT RESEARCH, 2009, 70 (08) : 601 - 615
  • [3] Cannabinoid 1 (CB1) Receptor - Pharmacology, Role in Pain and Recent Developments in Emerging CB1 Agonists
    Talwar, Rashmi
    Potluri, Vijay Kumar
    CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2011, 10 (05) : 536 - 544
  • [4] Alterations in behavioral flexibility by cannabinoid CB1 receptor agonists and antagonists
    Hill, Matthew N.
    Froese, Larissa M.
    Morrish, Anna C.
    Sun, Jane C.
    Floresco, Stan B.
    PSYCHOPHARMACOLOGY, 2006, 187 (02) : 245 - 259
  • [5] Alterations in behavioral flexibility by cannabinoid CB1 receptor agonists and antagonists
    Matthew N. Hill
    Larissa M. Froese
    Anna C. Morrish
    Jane C. Sun
    Stan B. Floresco
    Psychopharmacology, 2006, 187 : 245 - 259
  • [6] Cannabinoid CB1 receptor agonists produce cerebellar dysfunction in mice
    Patel, S
    Hillard, CJ
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2001, 297 (02): : 629 - 637
  • [7] Differentiation of CB1 cannabinoid agonists in rats
    Paronis, Carol Anne
    Martin, J.
    Shaller, N.
    Thakur, G. A.
    Teng, H.
    Zvonok, A.
    Makriyannis, A.
    Bergman, J.
    FASEB JOURNAL, 2009, 23
  • [8] Cannabinoid CB1 Receptor Antagonists
    Thomas, Brian F.
    DRUG DEVELOPMENT RESEARCH, 2009, 70 (08) : 525 - 526
  • [9] CB1 cannabinoid receptor ligands
    Thakur, GA
    Nikas, SP
    Makriyannis, A
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2005, 5 (07) : 631 - 640
  • [10] CB1 cannabinoid receptor antagonists
    Barth, F
    ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 40, 2005, 40 : 103 - 118